Amendment #1 to Project Rider #3, effective as of August 26, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
PROJECT RIDER #3
This Amendment #1 (Amendment #1) is entered into effective as of the date of the final signature executing this Amendment #1 (Amendment #1 Effective Date), by and between Magenta Therapeutics, Inc. (Magenta) and National Marrow Donor Program d/b/a Be The Match Biotherapies (BTMB), (each a Party and collectively the Parties) as those Parties are defined in Attachment A, Project Rider #3, effective September 6, 2018 (collectively, the Project Rider #3).
WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017, and Project Rider #3, effective September 6, 2018; and
WHEREAS, the Parties agree to extend the term of the Project Rider #3.
NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment to be effective as of the Amendment #1 Effective Date as follows:
Amendment to Project Rider #3
Delete the current term in Section D. Term of Project Rider #3 in its entirety and replace it with the following to read as follows:
The term of this Rider shall commence on the Rider effective date set forth above and continue in effect through [***].
This Amendment #1 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #1 Effective Date:
|MAGENTA THERAPEUTICS, INC.||NATIONAL MARROW DONOR PROGRAM d/b/a BE THE MATCH BIOTHERAPIES|
|Authorized Signature||Authorized Signature|
|(Typed/Printed Name)||(Typed/Printed Name)|
|Title:||VP Program Lead||Title:||Contracts & Procurement Director|